NASDAQ:CGIX - Cancer Genetics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.46 -0.03 (-6.12 %) (As of 11/19/2018 02:37 PM ET)Previous Close$0.49Today's Range$0.46 - $0.5252-Week Range$0.48 - $2.75Volume2,825 shsAverage Volume103,228 shsMarket Capitalization$13.68 millionP/E Ratio-0.64Dividend YieldN/ABeta1.1 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. Its clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. The company's discovery services offer the tools and testing methods for companies and researchers to identify and develop new compounds and molecular-based biomarkers for diagnostics and treatment of disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests; and has collaboration with Cellaria to develop precision medicine tools and platform technologies to support the development of new cancer therapeutics. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey. Receive CGIX News and Ratings via Email Sign-up to receive the latest news and ratings for CGIX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CGIX Previous Symbol CUSIPN/A Webwww.cancergenetics.com Phone201-528-9200 Debt Debt-to-Equity Ratio0.03 Current Ratio0.66 Quick Ratio0.66 Price-To-Earnings Trailing P/E Ratio-0.64 Forward P/E Ratio-0.79 P/E GrowthN/A Sales & Book Value Annual Sales$29.12 million Price / Sales0.44 Cash FlowN/A Price / CashN/A Book Value$0.97 per share Price / Book0.47 Profitability EPS (Most Recent Fiscal Year)($0.79) Net Income$-20,880,000.00 Net Margins-54.98% Return on Equity-81.99% Return on Assets-40.24% Miscellaneous Employees245 Outstanding Shares27,750,000Market Cap$13.68 million OptionableOptionable Cancer Genetics (NASDAQ:CGIX) Frequently Asked Questions What is Cancer Genetics' stock symbol? Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX." How were Cancer Genetics' earnings last quarter? Cancer Genetics Inc (NASDAQ:CGIX) released its quarterly earnings results on Tuesday, August, 14th. The medical research company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.16) by $0.03. The medical research company earned $7.04 million during the quarter, compared to analysts' expectations of $8.80 million. Cancer Genetics had a negative return on equity of 81.99% and a negative net margin of 54.98%. View Cancer Genetics' Earnings History. When is Cancer Genetics' next earnings date? Cancer Genetics is scheduled to release their next quarterly earnings announcement on Thursday, November 22nd 2018. View Earnings Estimates for Cancer Genetics. What price target have analysts set for CGIX? 3 brokerages have issued 1 year price targets for Cancer Genetics' stock. Their predictions range from $3.00 to $6.00. On average, they expect Cancer Genetics' share price to reach $4.50 in the next year. This suggests a possible upside of 878.3% from the stock's current price. View Analyst Price Targets for Cancer Genetics. What is the consensus analysts' recommendation for Cancer Genetics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cancer Genetics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cancer Genetics. What are Wall Street analysts saying about Cancer Genetics stock? Here are some recent quotes from research analysts about Cancer Genetics stock: 1. Maxim Group analysts commented, "Cancer Genetics reported revenue of $7.0M, down sequentially (8%) and a net loss of $3.6M. CGIX ended the period with $1.6M in cash, excluding $2.5M raised in July. We expect the company to raise more capital to continue its restructuring efforts. Key takeaway: While revenue is down, management is continuing to make progress implementing the restructuring strategy that we believe over time should position CGIX to streamline its cancer testing, biopharma and discovery business and return the company to growth. As such, 2018 should be viewed as a transition year for CGIX. We maintain a Hold rating." (8/14/2018) 2. According to Zacks Investment Research, "Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey. " (7/3/2018) Has Cancer Genetics been receiving favorable news coverage? Headlines about CGIX stock have been trending very positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cancer Genetics earned a daily sentiment score of 3.1 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. Who are some of Cancer Genetics' key competitors? Some companies that are related to Cancer Genetics include First Choice Healthcare Solutions (FCHS), CBA Florida (CBAI), OpGen (OPGN), Aeon Global Health (AGHC), Biocept (BIOC) and Foundation Medicine (FMI). Who are Cancer Genetics' key executives? Cancer Genetics' management team includes the folowing people: Mr. John A. Roberts MBA, Pres, CEO, COO & Director (Age 59)Mr. Michael Brian McCartney, Chief Commercial OfficerDr. Ralf Brandt, Pres of Discovery & Early Devel. Services (Age 55)Dr. Weiyi Chen Ph.D., HCLD, Director of Molecular DiagnosticsDr. Pal Singh-Kahlon Ph.D., FACMG, Director of Cytogenetics Who are Cancer Genetics' major shareholders? Cancer Genetics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Perkins Capital Management Inc. (4.64%), Renaissance Technologies LLC (2.43%) and Stonepine Capital Management LLC (2.21%). Company insiders that own Cancer Genetics stock include Geoffrey E Harris, Igor Gitelman, John A Roberts and John Pappajohn. View Institutional Ownership Trends for Cancer Genetics. Which institutional investors are selling Cancer Genetics stock? CGIX stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC. View Insider Buying and Selling for Cancer Genetics. Which institutional investors are buying Cancer Genetics stock? CGIX stock was acquired by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc. and Renaissance Technologies LLC. Company insiders that have bought Cancer Genetics stock in the last two years include Geoffrey E Harris, Igor Gitelman, John A Roberts and John Pappajohn. View Insider Buying and Selling for Cancer Genetics. How do I buy shares of Cancer Genetics? Shares of CGIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cancer Genetics' stock price today? One share of CGIX stock can currently be purchased for approximately $0.46. How big of a company is Cancer Genetics? Cancer Genetics has a market capitalization of $13.68 million and generates $29.12 million in revenue each year. The medical research company earns $-20,880,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Cancer Genetics employs 245 workers across the globe. What is Cancer Genetics' official website? The official website for Cancer Genetics is http://www.cancergenetics.com. How can I contact Cancer Genetics? Cancer Genetics' mailing address is 201 ROUTE 17 NORTH 2ND FLOOR, RUTHERFORD NJ, 07070. The medical research company can be reached via phone at 201-528-9200 or via email at [email protected] MarketBeat Community Rating for Cancer Genetics (NASDAQ CGIX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 211 (Vote Outperform)Underperform Votes: 153 (Vote Underperform)Total Votes: 364MarketBeat's community ratings are surveys of what our community members think about Cancer Genetics and other stocks. Vote "Outperform" if you believe CGIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGIX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/19/2018 by MarketBeat.com StaffFeatured Article: How is the S&P 500 index different from the DJIA?